



KC597

For research use only

Anti Human GRHPR Monoclonal Antibody


Clone No. 1H1

This product is generated from GANP® mice



Code No. KC597
Target GRHPR
Category Cancer
Gene ID 9380
Primary Source HGNC:4570
Synonyms PH2; GLXR; GLYD

Type Monoclonal Antibody
Immunogen Partial peptide of Human GRHPR (C-terminal region, 227-236aa)
Raised in GANP® mouse
Myeloma P3U1
Clone number 1H1
Purification ProteinG
Source Serum-free medium
Isotype IgG1, κ
Cross Reactivity Human, Rat
Label Unlabeled
Concentration 0.25 mg/mL
Contents (Volume) 50 μ g (200 μ L/vial)
Buffer PBS [containing 2% Block Ace as a stabilizer, 0.1% Proclin as a bacteriostat]
Storage Store at - 20°C long term, store at 4°C short term. Avoid repeated freeze-thaw cycles.
Application ELISA, IHC, WB



[IHC] Rat kidney tissue

ELISA	WB	IHC	ICC
1.0	10-20	5.0-10	Not tested
IP	FCM	IF	Neutralization
Not tested	Not tested	Not tested	Not tested

(μ g/mL)

Reference

- "Identification and expression of a cDNA for human hydroxypyruvate/glyoxylate reductase." Rumsby G. et al. Biochim. Biophys. Acta 1446:383-388(1999) [PubMed: 10524214] [Abstract]. Cited for: NUCLEOTIDE SEQUENCE [MRNA], SUBUNIT. Tissue: Liver.
- "The gene encoding hydroxypyruvate reductase (GRHPR) is mutated in patients with primary hyperoxaluria type II." Cramer S.D. et al. Hum. Mol. Genet. 8:2063-2069(1999) [PubMed: 10484776] [Abstract]. Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], INVOLVEMENT IN HP2. Tissue: Liver.
- Liu B. et al. Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases. Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. Tissue: Aorta.

UniPlot Summary

//Function Enzyme with hydroxy-pyruvate reductase, glyoxylate reductase and D-glycerate dehydrogenase enzymatic activities. Reduces hydroxypyruvate to D-glycerate, glyoxylate to glycolate oxidizes D-glycerate to hydroxypyruvate.

//Catalytic activity Glycolate + NADP⁺ = glyoxylate + NADPH. D-glycerate + NAD(P)⁺ = hydroxypyruvate + NAD(P)H.

//Subunit structure Homodimer.

//Tissue specificity Ubiquitous. Most abundantly expressed in the liver.

//Involvement in disease Defects in GRHPR are the cause of hyperoxaluria primary type 2 (HP2) [MIM:260000]; also known as primary hyperoxaluria type II (PH2). HP2 is a disorder where the main clinical manifestation is calcium oxalate nephrolithiasis though chronic as well as terminal renal insufficiency has been described. It is characterized by an elevated urinary excretion of oxalate and L-glycerate.

Manufactured by Trans Genic Inc.



COSMO BIO CO., LTD.

Inspiration for Life Science

TOYO 2CHOME, KOTO-KU, TOKYO, 135-0016, JAPAN

http://www.cosmobio.co.jp e-mail : export@cosmobio.co.jp

Phone : +81-3-5632-9617 FAX : +81-3-5632-9618